Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rapport Therapeutics
Biotech
Rapport's seizure drug hits in phase 2, sending stock soaring
Based on the data, Rapport plans to start two phase 3 trials of RAP-219 in the third quarter of 2026.
Nick Paul Taylor
Sep 8, 2025 8:25am
Sage CMO steps down amid pipeline struggles—Chutes & Ladders
Mar 7, 2025 8:30am
Why biotechs can benefit from the 'rational' IPO environment
Jan 24, 2025 10:30am
FDA places Rapport's nerve damage trial on hold
Nov 7, 2024 8:50am
Rapport upsizes IPO, tacking on $32M
Jun 7, 2024 11:00am
Rapport talks up $122M IPO for proof-of-concept epilepsy trials
Jun 3, 2024 7:10am
